Cover Image

Validation and application of an HPLC-UV method for routine therapeutic drug monitoring of dalbavancin

Dalbavancin is emerging as a promising alternative in the ambulant treatment of gram-positive infections that require long-term antibiotic treatment such as osteomyelitis, prosthetic joint infections, and endocarditis. The aim of the current study was to develop and validate a simple, rapid, and cos...

Full description

Saved in:
Bibliographic Details
Main Authors: Chiriac, Ute (Author) , Rau, Heike (Author) , Frey, Otto R. (Author) , Röhr, Anka C. (Author) , Klein, Sabrina (Author) , Meyer, Anna L. (Author) , Morath, Benedict (Author)
Format: Article (Journal)
Language:English
Published: 19 April 2022
In: Antibiotics
Year: 2022, Volume: 11, Issue: 5, Pages: 1-9
ISSN:2079-6382
DOI:10.3390/antibiotics11050541
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/antibiotics11050541
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2079-6382/11/5/541
Get full text
Author Notes:Ute Chiriac, Heike Rau, Otto R. Frey, Anka C. Röhr, Sabrina Klein, Anna L. Meyer and Benedict Morath

MARC

LEADER 00000caa a2200000 c 4500
001 1808696751
003 DE-627
005 20230426090946.0
007 cr uuu---uuuuu
008 220630s2022 xx |||||o 00| ||eng c
024 7 |a 10.3390/antibiotics11050541  |2 doi 
035 |a (DE-627)1808696751 
035 |a (DE-599)KXP1808696751 
035 |a (OCoLC)1341463323 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Chiriac, Ute  |e VerfasserIn  |0 (DE-588)1196234787  |0 (DE-627)1678100854  |4 aut 
245 1 0 |a Validation and application of an HPLC-UV method for routine therapeutic drug monitoring of dalbavancin  |c Ute Chiriac, Heike Rau, Otto R. Frey, Anka C. Röhr, Sabrina Klein, Anna L. Meyer and Benedict Morath 
264 1 |c 19 April 2022 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 30.06.2022 
500 |a This article belongs to the special issue "Therapeutic drug monitoring of antimicrobials" 
520 |a Dalbavancin is emerging as a promising alternative in the ambulant treatment of gram-positive infections that require long-term antibiotic treatment such as osteomyelitis, prosthetic joint infections, and endocarditis. The aim of the current study was to develop and validate a simple, rapid, and cost-effective high-performance liquid chromatography-ultraviolet spectrometry (HPLC-UV) method for the quantification of dalbavancin. Sample clean-up included a protein precipitation protocol, followed by chromatographic separation on a reverse phase HPLC column (C-18) with gradient elution of the mobile phase. Quantification was performed with the internal standard (caffeine) method. Linear relationships between peak area responses and drug concentrations were obtained in the range of 12.5-400 mg/L. The variation coefficient of precision and the bias of accuracy (both inter- and intraday) were less than 10%. The limit of quantification (LOQ) was 12.5 mg/L. The simple and reliable HPLC-UV assay described is a powerful tool for routine therapeutic drug monitoring (TDM) of dalbavancin in human serum in clinical laboratories. With a total process time of approximately 20 min, it allows for accurate and selective quantification up to the expected pharmacokinetic peak concentrations. The method was successfully used to analyze subsequent serum samples of three patients and showed good performance in monitoring serum levels. 
650 4 |a dalbavancin 
650 4 |a high performance liquid chromatography-ultraviolet spectrometry (HPLC-UV) 
650 4 |a pharmacokinetic/pharmacodynamics (PK/PD) 
650 4 |a therapeutic drug monitoring (TDM) 
700 1 |a Rau, Heike  |e VerfasserIn  |4 aut 
700 1 |a Frey, Otto R.  |e VerfasserIn  |4 aut 
700 1 |a Röhr, Anka C.  |e VerfasserIn  |4 aut 
700 1 |a Klein, Sabrina  |d 1982-  |e VerfasserIn  |0 (DE-588)138788715  |0 (DE-627)703106554  |0 (DE-576)309063922  |4 aut 
700 1 |a Meyer, Anna L.  |d 1977-  |e VerfasserIn  |0 (DE-588)130213896  |0 (DE-627)495058912  |0 (DE-576)298066866  |4 aut 
700 1 |a Morath, Benedict  |d 1989-  |e VerfasserIn  |0 (DE-588)1158503830  |0 (DE-627)1020514639  |0 (DE-576)503996769  |4 aut 
773 0 8 |i Enthalten in  |t Antibiotics  |d Basel : MDPI, 2012  |g 11(2022), 5, special issue, Artikel-ID 541, Seite 1-9  |h Online-Ressource  |w (DE-627)726120596  |w (DE-600)2681345-2  |w (DE-576)371374081  |x 2079-6382  |7 nnas  |a Validation and application of an HPLC-UV method for routine therapeutic drug monitoring of dalbavancin 
773 1 8 |g volume:11  |g year:2022  |g number:5  |g supplement:special issue  |g elocationid:541  |g pages:1-9  |g extent:9  |a Validation and application of an HPLC-UV method for routine therapeutic drug monitoring of dalbavancin 
856 4 0 |u https://doi.org/10.3390/antibiotics11050541  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.mdpi.com/2079-6382/11/5/541  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220630 
993 |a Article 
994 |a 2022 
998 |g 1158503830  |a Morath, Benedict  |m 1158503830:Morath, Benedict  |d 910000  |d 140000  |e 910000PM1158503830  |e 140000PM1158503830  |k 0/910000/  |k 0/140000/  |p 7 
998 |g 130213896  |a Meyer, Anna L.  |m 130213896:Meyer, Anna L.  |d 910000  |d 910200  |d 50000  |e 910000PM130213896  |e 910200PM130213896  |e 50000PM130213896  |k 0/910000/  |k 1/910000/910200/  |k 0/50000/  |p 6 
998 |g 138788715  |a Klein, Sabrina  |m 138788715:Klein, Sabrina  |d 910000  |d 911700  |e 910000PK138788715  |e 911700PK138788715  |k 0/910000/  |k 1/910000/911700/  |p 5 
998 |g 1196234787  |a Chiriac, Ute  |m 1196234787:Chiriac, Ute  |d 140000  |e 140000PC1196234787  |k 0/140000/  |p 1  |x j  |y j 
999 |a KXP-PPN1808696751  |e 4159479677 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 30.06.2022","This article belongs to the special issue \"Therapeutic drug monitoring of antimicrobials\""],"recId":"1808696751","person":[{"display":"Chiriac, Ute","roleDisplay":"VerfasserIn","role":"aut","given":"Ute","family":"Chiriac"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Heike","display":"Rau, Heike","family":"Rau"},{"family":"Frey","given":"Otto R.","roleDisplay":"VerfasserIn","role":"aut","display":"Frey, Otto R."},{"roleDisplay":"VerfasserIn","role":"aut","given":"Anka C.","display":"Röhr, Anka C.","family":"Röhr"},{"family":"Klein","given":"Sabrina","roleDisplay":"VerfasserIn","role":"aut","display":"Klein, Sabrina"},{"family":"Meyer","given":"Anna L.","roleDisplay":"VerfasserIn","role":"aut","display":"Meyer, Anna L."},{"family":"Morath","display":"Morath, Benedict","given":"Benedict","roleDisplay":"VerfasserIn","role":"aut"}],"language":["eng"],"name":{"displayForm":["Ute Chiriac, Heike Rau, Otto R. Frey, Anka C. Röhr, Sabrina Klein, Anna L. Meyer and Benedict Morath"]},"physDesc":[{"extent":"9 S."}],"id":{"eki":["1808696751"],"doi":["10.3390/antibiotics11050541"]},"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"19 April 2022"}],"relHost":[{"title":[{"title":"Antibiotics","title_sort":"Antibiotics","subtitle":"open access journal"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedKey":"2012","publisherPlace":"Basel","publisher":"MDPI","dateIssuedDisp":"2012-"}],"disp":"Validation and application of an HPLC-UV method for routine therapeutic drug monitoring of dalbavancinAntibiotics","language":["eng"],"note":["Gesehen am 12.09.12"],"recId":"726120596","part":{"volume":"11","issue":"5","text":"11(2022), 5, special issue, Artikel-ID 541, Seite 1-9","extent":"9","year":"2022","pages":"1-9"},"pubHistory":["1.2012 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"eki":["726120596"],"zdb":["2681345-2"],"issn":["2079-6382"]}}],"title":[{"title_sort":"Validation and application of an HPLC-UV method for routine therapeutic drug monitoring of dalbavancin","title":"Validation and application of an HPLC-UV method for routine therapeutic drug monitoring of dalbavancin"}]} 
SRT |a CHIRIACUTEVALIDATION1920 

Similar Items